103 related articles for article (PubMed ID: 1419630)
21. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies.
Cicardi M; Zingale LC; Pappalardo E; Folcioni A; Agostoni A
Medicine (Baltimore); 2003 Jul; 82(4):274-81. PubMed ID: 12861105
[TBL] [Abstract][Full Text] [Related]
22. The critical concentration of C1-esterase inhibitor (C1-INH) in human serum preventing auto-activation of the first component of complement (C1).
Windfuhr JP; Alsenz J; Loos M
Mol Immunol; 2005 Apr; 42(6):657-63. PubMed ID: 15781109
[TBL] [Abstract][Full Text] [Related]
23. [Hereditary angioedema: changes in serum levels of C4 in response to danazol].
Egidio Fabiani J; Squiquera L; Leoni J; Simkin G; Casala A
Med Cutan Ibero Lat Am; 1987; 15(6):461-7. PubMed ID: 3323703
[TBL] [Abstract][Full Text] [Related]
24. Prospective analysis of C1 dissociation and complement activation in patients with systemic lupus erythematosus.
Jonsson H; Sturfelt G; Mårtensson U; Truedsson L; Sjöholm AG
Clin Exp Rheumatol; 1995; 13(5):573-80. PubMed ID: 8575134
[TBL] [Abstract][Full Text] [Related]
25. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study.
Fattouch K; Bianco G; Speziale G; Sampognaro R; Lavalle C; Guccione F; Dioguardi P; Ruvolo G
Eur J Cardiothorac Surg; 2007 Aug; 32(2):326-32. PubMed ID: 17576071
[TBL] [Abstract][Full Text] [Related]
26. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
Doekes G; van Es LA; Daha MR
Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
[TBL] [Abstract][Full Text] [Related]
27. Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment.
Bekos C; Perkmann T; Krauth M; Raderer M; Lechner K; Jaeger U
Leuk Lymphoma; 2016 Sep; 57(9):2033-6. PubMed ID: 26795750
[TBL] [Abstract][Full Text] [Related]
28. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor.
Veerhuis R; Janssen I; De Groot CJ; Van Muiswinkel FL; Hack CE; Eikelenboom P
Exp Neurol; 1999 Nov; 160(1):289-99. PubMed ID: 10630213
[TBL] [Abstract][Full Text] [Related]
29. Plasma C1 inhibitor in malignant diseases: functional activity versus concentration.
Starcević D; Jelić-Ivanović Z; Kalimanovska V
Ann Clin Biochem; 1991 Nov; 28 ( Pt 6)():595-8. PubMed ID: 1776810
[TBL] [Abstract][Full Text] [Related]
30. C1-inhibitor--biochemical properties and clinical applications.
Al-Abdullah IH; Greally J
Crit Rev Immunol; 1985; 5(4):317-30. PubMed ID: 3899511
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases.
Woo P; Lachmann PJ; Harrison RA; Amos N; Cooper C; Rosen FS
Clin Exp Immunol; 1985 Jul; 61(1):1-8. PubMed ID: 4042415
[TBL] [Abstract][Full Text] [Related]
32. In vitro effects of organic solvents on immunity indicators in serum.
Stefanovic J; Starsia Z; Murgasová I; Absolonová O
J Hyg Epidemiol Microbiol Immunol; 1987; 31(1):1-7. PubMed ID: 3571967
[TBL] [Abstract][Full Text] [Related]
33. Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema.
Kelemen Z; Moldovan D; Mihály E; Visy B; Széplaki G; Csuka D; Füst G; Farkas H; Varga L
Clin Immunol; 2010 Mar; 134(3):354-8. PubMed ID: 19945350
[TBL] [Abstract][Full Text] [Related]
34. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema.
Cicardi M; Beretta A; Colombo M; Gioffré D; Cugno M; Agostoni A
Clin Exp Immunol; 1996 Dec; 106(3):475-80. PubMed ID: 8973615
[TBL] [Abstract][Full Text] [Related]
35. Activation of the ficolin-lectin pathway during attacks of hereditary angioedema.
Csuka D; Munthe-Fog L; Hein E; Zotter Z; Prohászka Z; Farkas H; Varga L; Garred P
J Allergy Clin Immunol; 2014 Dec; 134(6):1388-1393.e1. PubMed ID: 25042985
[TBL] [Abstract][Full Text] [Related]
36. Low c1-inhibitor levels predict early restenosis after eversion carotid endarterectomy.
Széplaki G; Varga L; Laki J; Dósa E; Rugonfalvi-Kiss S; Madsen HO; Prohászka Z; Kocsis A; Gál P; Szabó A; Acsády G; Karádi I; Selmeci L; Garred P; Füst G; Entz L
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2756-62. PubMed ID: 17916775
[TBL] [Abstract][Full Text] [Related]
37. The acquired C1-INH deficiencies with autoantibodies (AAE type II).
Alsenz J; Loos M
Behring Inst Mitt; 1989 Jul; (84):165-72. PubMed ID: 2679532
[TBL] [Abstract][Full Text] [Related]
38. Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 INH that inhibits C1-s but not C1-r.
Wisnieski JJ; Knauss TC; Yike I; Dearborn DG; Narvy RL; Naff GB
J Immunol; 1994 Mar; 152(6):3199-209. PubMed ID: 8144914
[TBL] [Abstract][Full Text] [Related]
39. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
Ziccardi RJ
J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
[TBL] [Abstract][Full Text] [Related]
40. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
